AllianceBernstein’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.8M | Buy |
119,820
+1,200
| +1% | +$28.6K | ﹤0.01% | 1818 |
|
|
2025
Q4 | $2.77M | Sell |
118,620
-4,685
| -4% | -$104K | ﹤0.01% | 1828 |
|
|
2025
Q3 | $2.43M | Buy |
123,305
+75
| +0.1% | +$1.54K | ﹤0.01% | 1892 |
|
|
2025
Q2 | $2.67M | Buy |
123,230
+3,100
| +3% | +$73.2K | ﹤0.01% | 1788 |
|
|
2025
Q1 | $2.91M | Buy |
120,130
+4,610
| +4% | +$104K | ﹤0.01% | 1704 |
|
|
2024
Q4 | $2.41M | Sell |
115,520
-4,522
| -4% | -$97.1K | ﹤0.01% | 1865 |
|
|
2024
Q3 | $2.39M | Sell |
120,042
-5,700
| -5% | -$106K | ﹤0.01% | 1871 |
|
|
2024
Q2 | $1.95M | Buy |
125,742
+8,590
| +7% | +$134K | ﹤0.01% | 1969 |
|
|
2024
Q1 | $1.87M | Hold |
117,152
| – | – | ﹤0.01% | 1955 |
|
|
2023
Q4 | $1.97M | Buy |
117,152
+4,100
| +4% | +$56K | ﹤0.01% | 1947 |
|
|
2023
Q3 | $1.32M | Sell |
113,052
-186,030
| -62% | -$2.49M | ﹤0.01% | 2095 |
|
|
2023
Q2 | $4.02M | Buy |
299,082
+162,460
| +119% | +$2.34M | ﹤0.01% | 1521 |
|
|
2023
Q1 | $2.27M | Sell |
136,622
-14,131
| -9% | -$233K | ﹤0.01% | 1799 |
|
|
2022
Q4 | $2.8M | Sell |
150,753
-3,946
| -3% | -$60.8K | ﹤0.01% | 1715 |
|
|
2022
Q3 | $1.99M | Sell |
154,699
-363,012
| -70% | -$4.3M | ﹤0.01% | 1893 |
|
|
2022
Q2 | $3.63M | Buy |
517,711
+383,311
| +285% | +$2.81M | ﹤0.01% | 1606 |
|
|
2022
Q1 | $1.11M | Buy |
134,400
+500
| +0.4% | +$3.54K | ﹤0.01% | 2386 |
|
|
2021
Q4 | $907K | Hold |
133,900
| – | – | ﹤0.01% | 2508 |
|
|
2021
Q3 | $710K | Sell |
133,900
-8,048
| -6% | -$44K | ﹤0.01% | 2628 |
|
|
2021
Q2 | $816K | Hold |
141,948
| – | – | ﹤0.01% | 2618 |
|
|
2021
Q1 | $654K | Sell |
141,948
-14,839
| -9% | -$59K | ﹤0.01% | 2575 |
|
|
2020
Q4 | $524K | Buy |
156,787
+7,987
| +5% | +$26.8K | ﹤0.01% | 2566 |
|
|
2020
Q3 | $442K | Hold |
148,800
| – | – | ﹤0.01% | 2582 |
|
|
2020
Q2 | $687K | Hold |
148,800
| – | – | ﹤0.01% | 2412 |
|
|
2020
Q1 | $573K | Hold |
148,800
| – | – | ﹤0.01% | 2281 |
|
|
2019
Q4 | $558K | Hold |
148,800
| – | – | ﹤0.01% | 2507 |
|
|
2019
Q3 | $790K | Hold |
148,800
| – | – | ﹤0.01% | 2347 |
|
|
2019
Q2 | $571K | Buy |
148,800
+59,700
| +67% | +$258K | ﹤0.01% | 2544 |
|
|
2019
Q1 | $454K | Buy |
89,100
+42,600
| +92% | +$125K | ﹤0.01% | 2557 |
|
|
2018
Q4 | $89K | Buy |
46,500
+10,100
| +28% | +$28.9K | ﹤0.01% | 3007 |
|
|
2018
Q3 | $138K | Buy |
36,400
+7,200
| +25% | +$22.6K | ﹤0.01% | 3044 |
|
|
2018
Q2 | $91K | Buy |
29,200
+11,500
| +65% | +$34.9K | ﹤0.01% | 3061 |
|
|
2018
Q1 | $42K | Buy |
17,700
+7,300
| +70% | +$24.3K | ﹤0.01% | 2997 |
|
|
2017
Q4 | $41K | Sell |
10,400
-1,400
| -12% | -$4.63K | ﹤0.01% | 3005 |
|
|
2017
Q3 | $30K | Hold |
11,800
| – | – | ﹤0.01% | 3086 |
|
|
2017
Q2 | $33K | Buy |
+11,800
| New | +$24.6K | ﹤0.01% | 3133 |
|
|
2014
Q2 | – | Sell |
-364
| Closed | -$1K | – | 3441 |
|
|
2014
Q1 | $1K | Hold |
364
| – | – | ﹤0.01% | 3520 |
|
|
2013
Q4 | $1K | Hold |
364
| – | – | ﹤0.01% | 3321 |
|
|
2013
Q3 | $1K | Buy |
+364
| New | +$612 | ﹤0.01% | 3349 |
|
Other funds holding CPRX
VCM
DM
VPM
AllianceBernstein's CPRX Position: Q1 2026 in Review
AllianceBernstein increased its Catalyst Pharmaceutical (CPRX) stake by 1% in Q1 2026, buying an estimated $28.6K and bringing the position to 119,820 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1818.
AllianceBernstein first reported a position in CPRX in Q3 2013 and has held it in 39 quarters since. The position peaked at $4.02M in Q2 2023. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- AllianceBernstein held 119,820 shares of Catalyst Pharmaceutical worth $2.8M as of Q1 2026.
- AllianceBernstein bought 1,200 Catalyst Pharmaceutical shares in Q1 2026, an estimated $28.6K.
- Catalyst Pharmaceutical made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #1818 holding.
- AllianceBernstein first reported a position in Catalyst Pharmaceutical in Q3 2013 and has held it in 39 quarters since.
- AllianceBernstein's Catalyst Pharmaceutical position peaked at $4.02M in Q2 2023.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.